Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
Bristol Myers Squibb cash
Cash and short-term investments held at the end of each period.
Bristol Myers Squibb's cash was $12.58B at Sep 30, 2026. For fiscal 2025 it was $10.67B, down 1.7% from the year before. Over ten years it grew 9.6% a year on average. The highest annual figure on record is $17.30B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.67B | -1.7% |
| FY2024 | Dec 31, 2024 | $10.86B | -12.0% |
| FY2023 | Dec 31, 2023 | $12.34B | +30.5% |
| FY2022 | Dec 31, 2022 | $9.46B | -45.4% |
| FY2021 | Dec 31, 2021 | $17.30B | +6.4% |
| FY2020 | Dec 31, 2020 | $16.26B | +2.5% |
| FY2019 | Dec 31, 2019 | $15.87B | +81.2% |
| FY2018 | Dec 31, 2018 | $8.76B | +28.6% |
| FY2017 | Dec 31, 2017 | $6.81B | +7.3% |
| FY2016 | Dec 31, 2016 | $6.35B | +48.7% |
| FY2015 | Dec 31, 2015 | $4.27B | -42.6% |
| FY2014 | Dec 31, 2014 | $7.44B | +64.3% |
| FY2013 | Dec 31, 2013 | $4.53B | +60.0% |
| FY2012 | Dec 31, 2012 | $2.83B | -67.6% |
| FY2011 | Dec 31, 2011 | $8.73B | +19.6% |
| FY2010 | Dec 31, 2010 | $7.30B | -14.2% |
| FY2009 | Dec 31, 2009 | $8.51B | +3.0% |
| FY2008 | Dec 31, 2008 | $8.27B | +358.9% |
| FY2007 | Dec 31, 2007 | $1.80B | -10.8% |
| FY2006 | Dec 31, 2006 | $2.02B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.58B | -23.8% |
| Q2 FY2026 | Jun 30, 2026 | $11.07B | -18.7% |
| Q1 FY2026 | Mar 31, 2026 | $10.49B | -11.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.67B | -1.7% |
| Q3 FY2025 | Sep 30, 2025 | $16.50B | +103.8% |
| Q2 FY2025 | Jun 30, 2025 | $13.62B | +104.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.78B | +21.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.86B | -12.0% |
| Q3 FY2024 | Sep 30, 2024 | $8.10B | +4.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.66B | -24.2% |
| Q1 FY2024 | Mar 31, 2024 | $9.67B | +3.8% |
| Q4 FY2023 | Dec 31, 2023 | $12.34B | +30.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.74B | -16.3% |
| Q2 FY2023 | Jun 30, 2023 | $8.78B | -34.6% |
| Q1 FY2023 | Mar 31, 2023 | $9.32B | -38.6% |
| Q4 FY2022 | Dec 31, 2022 | $9.46B | -45.4% |
| Q3 FY2022 | Sep 30, 2022 | $9.25B | -42.2% |
| Q2 FY2022 | Jun 30, 2022 | $13.44B | +0.7% |
| Q1 FY2022 | Mar 31, 2022 | $15.18B | +14.4% |
| Q4 FY2021 | Dec 31, 2021 | $17.30B | +6.4% |
| Q3 FY2021 | Sep 30, 2021 | $16.00B | -25.8% |
| Q2 FY2021 | Jun 30, 2021 | $13.34B | -39.6% |
| Q1 FY2021 | Mar 31, 2021 | $13.27B | -29.2% |
| Q4 FY2020 | Dec 31, 2020 | $16.26B | +2.5% |
| Q3 FY2020 | Sep 30, 2020 | $21.58B | -33.7% |
| Q2 FY2020 | Jun 30, 2020 | $22.09B | -24.8% |
| Q1 FY2020 | Mar 31, 2020 | $18.75B | +114.0% |
| Q4 FY2019 | Dec 31, 2019 | $15.87B | +81.2% |
| Q3 FY2019 | Sep 30, 2019 | $32.54B | +376.5% |
| Q2 FY2019 | Jun 30, 2019 | $29.36B | +383.2% |
| Q1 FY2019 | Mar 31, 2019 | $8.76B | +29.5% |
| Q4 FY2018 | Dec 31, 2018 | $8.76B | +28.6% |
| Q3 FY2018 | Sep 30, 2018 | $6.83B | -4.1% |
| Q2 FY2018 | Jun 30, 2018 | $6.08B | -6.6% |
| Q1 FY2018 | Mar 31, 2018 | $6.77B | +10.8% |
| Q4 FY2017 | Dec 31, 2017 | $6.81B | +7.3% |
| Q3 FY2017 | Sep 30, 2017 | $7.12B | – |
| Q2 FY2017 | Jun 30, 2017 | $6.51B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.11B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.35B | – |
See a number that looks wrong?